Relypsa Revenue and Competitors

Location

$656.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Relypsa's estimated annual revenue is currently $13.9M per year.(i)
  • Relypsa's estimated revenue per employee is $155,000
  • Relypsa's total funding is $656.6M.

Employee Data

  • Relypsa has 90 Employees.(i)
  • Relypsa grew their employee count by -25% last year.

Relypsa's People

NameTitleEmail/Phone
1
DirectorReveal Email/Phone
2
Territory Account ManagerReveal Email/Phone
3
Senior Division Sales ManagerReveal Email/Phone
4
Territory Account ManagerReveal Email/Phone
5
Senior Medical Director; Drug Safety and PharmacovigilanceReveal Email/Phone
6
Territory Account ManagerReveal Email/Phone
7
Sr Salesforce/Veeva ConsultantReveal Email/Phone
8
Territory Account ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Relypsa?

Relypsa, Inc. is a privately held biopharmaceutical company leading the discovery and development of new non-absorbed polymeric drugs for important applications in renal and cardiovascular disease. The company’s most advanced therapeutic programs include a novel potassium binder for treatment of hyperkalemia, known as ILY-105, as well as a novel sodium binder, ILY102, for the potential treatment of congestive heart failure. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform. To date, Relypsa has raised $33 million in Series A financing. Investors include 5AM Ventures, New Leaf Venture Partners, Delphi Ventures, CMEA Ventures and Mediphase Venture Partners.

keywords:Biotechnology, Healthcare

$656.6M

Total Funding

90

Number of Employees

$13.9M

Revenue (est)

-25%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Relypsa News

2022-03-30 - Pathalys Pharma Announces Executive Team Appointments

... his niche building early-stage commercial organizations at companies such as Oscient Pharmaceuticals, AMAG Pharmaceuticals and Relypsa.

2010-09-13 - Relypsa Raises $70M in Series B Financing

Relypsa, Inc., a Santa Clara, CA-based biopharmaceutical company developing non-absorbed polymeric drugs, completed a $70m Series B financing. The round was led by OrbiMed Advisors, LLC, with participation from existing investors New Leaf Venture Partners, 5AM Ventures, Delphi Ventures, Sprout ...

2009-03-11 - Heart drug co. Relypsa gets $10M more to complete trials

Pharmaceutical company Relypsa announced that its investors extended its first round of funding by $10 million to a total $43 million to help it finish phase-two clinical trials on its lead drug candidate, a treatment that could alleviate symptoms of heart failure and chronic kidney disease. Ba ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$18.5M90-6%N/A
#2
$12.7M91-1%$48M
#3
$13.2M9157%$22.6M
#4
$14.3M920%N/A
#5
$15.2M926%N/A